It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
To determine the growth inhibition capability of all-trans retinoic acid (ATRA) with cytokine-induced killer cells (CIKs), we evaluated their effects, alone and in combination, on human lung carcinoma A549 cells. CIKs treated with ATRA significantly inhibited cell growth. Additionally, CIK with ATRA synergistically inhibited migration and invasiveness, colony formation of A549 and NCI-H520 cells. Furthermore, analysis of apoptosis markers Bcl-2, Bax, Survivin and cleaved Caspase-3 showed that Bcl-2 and Survivin mRNA levels significantly decreased, and that Bax mRNA significantly increased, in the CIK + ATRA-treated cells, with corresponding effects on their respective proteins. The involved mechanisms may be associated with upregulated expression of MHC class I-Related Chain (MICA) and interleukin (IL)-2. These results suggest that administration of combined CIK and ATRA is a potentially novel treatment for lung carcinoma.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, People’s Republic of China
2 Department of Clinical Bio-Cell, 4th Hospital, Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China; Research Center, 4th Hospital, Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China
3 Research Center, 4th Hospital, Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China
4 Department of Surgery, Number One Hospital of Shijiazhuang, Shijiazhuang, Hebei, People’s Republic of China
5 Department of Clinical Bio-Cell, 4th Hospital, Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China